Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.
Li J, Xue Z, Wu Z, Bi L, Liu H, Wu L, Liu S, Huang X, Wang Y, Zhang Y, Qi W, He L, Dai L, Sun L, Li X, Shuai Z, Zhao Y, Wang Y, Xu J, Zhang H, Yu H, Chen X, Bao C.
Li J, et al. Among authors: li x.
Clin Rheumatol. 2022 Oct;41(10):3005-3016. doi: 10.1007/s10067-022-06199-8. Epub 2022 Jun 8.
Clin Rheumatol. 2022.
PMID: 35676450
Clinical Trial.